Distinguished Innovator in Genomics Joins the Scientific Advisory Board of Predictive Oncology
Marc Malandro POAI Scientific Advisory BoardEAGAN, Minn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the...
Cancer
vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer
Steven Tuch, Chief Financial Officer Steven Tuch, Chief Financial Officer Steven Tuch, Chief Financial Officer HIGH POINT, N.C., Dec. 13,...
Investigators Present Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting
Patients treated in dose-escalation portion of Phase 1/2 study evaluating seclidemstat in combination with azacitidine 50% overall response rate among...
ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical...
Alpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event During J.P. Morgan Healthcare Conference in San Francisco in January 2023
JERUSALEM, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau," or the “Company”), the...
Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
In December 2022, the 15th patient was dosed with IMX-110IMX-110 clinical trial data expected to be released on a rolling...
Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting
Significant single-agent activity in diffuse large B-cell lymphoma (DLBCL) cell models and in mouse model showed superiority to lenalidomide (Revlimid®)...
BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences
Additional analyses of non-small cell lung cancer (NSCLC) studies support the efficacy of plinabulin monotherapy in reducing the mean duration...
Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors
ERAS-3490, an orally available small molecule KRAS G12C inhibitor, has demonstrated robust nonclinical CNS and systemic activitySAN DIEGO, Dec. 13,...
AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer
Accomplished scientist with a diverse range of skills from general wet lab technique to company-wide operations managementOCALA, Fla., Dec. 12,...
Femasys Inc. Reports Encouraging Promotional Launch of FemCerv at AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons
--FemCerv®, the first endocervical tissue sampler of its kind in the detection of cervical cancer, was well-received after being presented...
Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
CARLSBAD, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life...
UM171 cell therapy demonstrates improved outcomes compared to cord and matched unrelated donor peripheral blood transplants in real-world setting
MONTRÉAL, Dec. 12, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation,...
Genmab to Hold 2022 R&D Update and ASH Data Review Meeting
Media Release Event to be held live in New Orleans, LouisianaMeeting to be webcast live and archived on www.genmab.com Copenhagen,...
Starton Therapeutics’ STAR-LLD Continuous Delivery Shows Superior Tumor Reduction and Progression Free Survival (PFS) Compared to Pulsatile Lenalidomide Treatment in Lenalidomide-Resistant Model
STAR-LLD, a continuous delivery system of lenalidomide in development by Starton Therapeutics, was recently evaluated in a preclinical efficacy study...
Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company
- $30M Series A investment from Versant Ventures and NEA- CAMBRIDGE, Mass. and NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE)...
Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date
BMF-500, an investigational third generation covalent FLT3 inhibitor, demonstrated preclinically: Picomolar affinity to activating FLT3 mutations including FLT3-ITD and various...
Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial
CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to...
Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea
DARE-PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted for 2023 2022...
ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing
LOS ANGELES, CA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company...